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Ziprasidone IM is a short-acting formulation indicated for
the rapid control of agitation in patients with schizophre-
nia, when oral therapy is not appropriate. It is usually
used for a maximum of 3 consecutive days. The recom-
mended dosing is 10 mg administered as required up to a
maximum dose of 40 mg/day and doses of 10 mg may be
administered every 2 hours. Some patients may require an
initial dose of 20 mg, which can be followed by a further
dose of 10 mg after 4 hours. Thereafter, doses of 10 mg
may be given every 2 hours up to the maximum daily dose
of 40 mg. This preparation is only for intramuscular use
and may be used concomitantly with benzodiazepines.
Several controlled clinical trials have documented the
safety and efficacy of Ziprasidone IM when used as
described in the package insert. In a the 7-day study versus
haloperidol Ziprasidone IM was superior to haloperidol
IM in reducing symptoms of acute schizophrenia as meas-
ured by the BPRS and CGI-S scales. Ziprasidone also dem-
onstrated significantly greater improvement than
haloperidol in the BPRS total score in a 6-week study ver-
sus haloperidol at the end of the IM phase. Finally, the
transition from IM to oral therapy was smooth, with con-
tinued improvement in efficacy, as measured by the BPRS
total score. In the United States accreditation of Mental
Health facilities includes close scrutiny of every episode of
restraint in acute psychiatry. Documentation of each epi-
sode is carefully verified and data collected longitudinally.
Every effort needs to be made to make episodes few as
possible and short as possible. I will discuss how Ziprasi-
done IM can play a role in the attempt to reduce duration
of episodes of restraint.
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